Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

(2019) Aliza Thompson et al.   Clinical Journal of the American Society of Nephrology

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

(2019) Hiddo J L Heerspink et al.   Lancet Diabetes & Endocrinology

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials

(2019) Lesley A. Inker et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Performance of GFR Slope as a Surrogate Endpoint for Kidney Disease Progression in Clinical Trials: A Statistical Simulation

(2019) Tom Greene et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data

(2019) Morgan E. Grams et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney disease

(2019) Edward Vonesh et al.   STATISTICS IN MEDICINE

Change in Albuminuria and Estimated GFR as End Points for Clinical Trials in Early Stages of CKD: A Perspective From European Regulators

(2019) Frank Holtkamp et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Change in Estimated GFR and Albuminuria as End Points in Clinical Trials: A Viewpoint From the FDA

(2019) Aliza Thompson et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy

(2017) Jicheng Lv et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis

(2016) Lesley A. Inker et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy

(2015) Thomas Rauen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Conducting Meta-Analyses inRwith themetaforPackage

(2015) Wolfgang Viechtbauer   Journal of Statistical Software

Early Change in Proteinuria as a Surrogate End Point for Kidney Disease Progression: An Individual Patient Meta-analysis

(2014) Lesley A. Inker et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials

(2014) Lesley A. Inker et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

(2014) Andrew S. Levey et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality

(2014) Josef Coresh et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments

(2014) Rosanna Coppo et al.   KIDNEY INTERNATIONAL

Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy

(2014) Koichi Kamei et al.   PEDIATRIC NEPHROLOGY

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Risk Stratification of Patients With IgA Nephropathy

(2012) Sean J. Barbour et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy

(2012) Miho Tatematsu et al.   Clinical and Experimental Nephrology

The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy

(2012) Keita Hirano et al.   Clinical and Experimental Nephrology

IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine

(2012) Claudio Pozzi et al.   JOURNAL OF NEPHROLOGY

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

(2012) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Addition of Azathioprine to Corticosteroids Does Not Benefit Patients with IgA Nephropathy

(2010) C. Pozzi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification

(2009) Daniel C. Cattran et al.   KIDNEY INTERNATIONAL

Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy

(2009) C. Manno et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION